Home About us Current issue Ahead of Print Back issues Submission Instructions Advertise Contact Login   

Search Article 
  
Advanced search 
 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 2307 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 

ORIGINAL ARTICLE Table of Contents   
Year : 2015  |  Volume : 26  |  Issue : 1  |  Page : 47-55
Rituximab as a rescue therapy in patients with glomerulonephritis


1 The Saudi Center for Organ Transplantation, Riyadh, Saudi Arabia
2 King Khaled University Hospital, Riyadh, Saudi Arabia
3 Prince Sultan Military Medical Center, Riyadh, Saudi Arabia
4 King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
5 Armed Forces Hospital, Jeddah, Saudi Arabia
6 King Fahad Hospital, Jeddah, Saudi Arabia
7 King Abdulaziz Hospital, Jeddah, Saudi Arabia
8 King Fahad Medical City, Riyadh, Saudi Arabia
9 King Fahad Hospital of the University, Alkhober, Saudi Arabia
10 Security Forces Hospital, Riyadh, Saudi Arabia
11 Dammam Medical Complex, Dammam, Saudi Arabia

Correspondence Address:
Muhammad Ziad Souqiyyeh
Saudi Center for Organ Transplantation, P. O. Box 27049, Riyadh 11417
Saudi Arabia
Login to access the Email id


Read associated Erratum: Erratum with this article

DOI: 10.4103/1319-2442.148733

PMID: 25579715

Rights and Permissions

To evaluate the use of rituximab in the treatment of severe glomerulonephritis (GN) in order to prevent progression of kidney disease toward the end stage, we designed a multicenter, retrospective study in Saudi Arabia about the efficacy and safety of the use of "off label" rituximab in a variety of severe refractory GN to conventional treatment and the progression of kidney disease for at least one year of follow-up. All the patients had kidney biopsies before treatment with rituximab, and proteinuria and glomerular filtration rate (GFR) were followed-up for the period of the study. The immediate side-effect at the time of administration of rituximab included itching in three patients, hypotension in one patient and anaphylaxis in one patient (dropped out from the study). After the administration of rituximab in 42 patients and during the first six months of therapy, 16 (38%) patients had complete remission (CR), 13 (31%) patients had partial remission (PR) and 13 (31%) patients had no remission. The mean follow-up period for the patients was 19.0 ± 6.97 months (median 18.0 months). The long-term follow-up during the study period disclosed a good hospitalization record for almost all of the patients. Membranous GN (MGN) was the largest group in the cohort (58% of the patients), and we observed CR and PR in 40% and 28% of them, respectively, which was comparable with the previous experience with rituximab in MGN patients with more CR than PR in our cohort. We conclude that our study suggests the safety and efficacy of the use of rituximab in patients with refractory GN and that larger and long-term prospective studies are required to define the role of rituximab in the different categories of these diseases.


[FULL TEXT] [PDF]*
Print this article  Email this article
    

  Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Citation Manager
  Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed4773    
    Printed64    
    Emailed0    
    PDF Downloaded812    
    Comments [Add]    

Recommend this journal